Get Updates

David Marks, MBBS, PhD

Dr. Marks is the Chief Medical Officer at Immix Biopharma. Prior to Immix, Dr. Marks has held positions of increasing responsibility and most recently been the Director and Lead Clinician at Bristol Allogenic Adult Bone Marrow Transplant Unit and a Professor in Hematology and Stem Cell Transplantation in the Department of Molecular and Cellular Medicine, University of Bristol from 1998 until 2022.

At the University Hospitals Bristol NHS Trust, Dr. Marks has been a hematology/oncology CAR-T expert, having been appointed as expert who evaluated trials resulting in regulatory approval of CAR-Ts Tisagenlecleucel (KYMRIAH®) (Novartis) and Brexucabtagene autoleucel (TECARTUS®) (Kite/Gilead). Dr. Marks was also a principal investigator in trials resulting in regulatory approval of Inotuzumab (BESPONSA®) (Pfizer) and played a key role in gaining approval for rituximab in adult ALL (RITUXAN®) (Genentech/Biogen). Dr. Marks also has experience working with idecabtagene vicleucel (ABECMA®) and allogeneic CAR-T therapies currently in clinical trials.

Dr. Marks was the Medical Director of the IMPACT UK from 2016 until 2020, a partnership of organizations committed to improving the outcomes of stem cell transplant patients through the delivery of clinical trials across the UK jointly funded by Anthony Nolan, Leukemia UK and NHS Blood and Transplant.

Dr Marks was President of the British Society of Blood and Marrow Transplantation between 2007 and 2009 and established the Society’s Clinical Trials Committee in 1999. Prior, Dr, Marks was an assistant professor of basic research in leukemia and bone marrow transplantation in the division of hematology oncology, Department of medicine at the Drexel University College of Medicine in Philadelphia, PA from 1993 until 1996.

Dr. Marks is an author of more than 10 book chapters and more than 310 peer reviewed publications, including in the New England Journal of Medicine, Lancet Oncology, Blood, and the Journal of Clinical Oncology. Dr. Marks received his MBBS and PhD from the University of Melbourne.

 Dr. Marks is the Chief Medical Officer at Immix Biopharma. Prior to Immix, Dr. Marks has held positions of increasing responsibility and most recently been the Director and Lead Clinician at Bristol Allogenic Adult Bone Marrow Transplant Unit and a Professor in Hematology and Stem Cell Transplantation in the Department of Molecular and Cellular Medicine, University of Bristol from 1998 until 2022.

At the University Hospitals Bristol NHS Trust, Dr. Marks has been a hematology/oncology CAR-T expert, having been appointed as expert who evaluated trials resulting in regulatory approval of CAR-Ts Tisagenlecleucel (KYMRIAH®) (Novartis) and Brexucabtagene autoleucel (TECARTUS®) (Kite/Gilead). Dr. Marks was also a principal investigator in trials resulting in regulatory approval of Inotuzumab (BESPONSA®) (Pfizer) and played a key role in gaining approval for rituximab in adult ALL (RITUXAN®) (Genentech/Biogen). Dr. Marks also has experience working with idecabtagene vicleucel (ABECMA®) and allogeneic CAR-T therapies currently in clinical trials.

Dr. Marks was the Medical Director of the IMPACT UK from 2016 until 2020, a partnership of organizations committed to improving the outcomes of stem cell transplant patients through the delivery of clinical trials across the UK jointly funded by Anthony Nolan, Leukemia UK and NHS Blood and Transplant.

Dr Marks was President of the British Society of Blood and Marrow Transplantation between 2007 and 2009 and established the Society’s Clinical Trials Committee in 1999. Prior, Dr, Marks was an assistant professor of basic research in leukemia and bone marrow transplantation in the division of hematology oncology, Department of medicine at the Drexel University College of Medicine in Philadelphia, PA from 1993 until 1996.

Dr. Marks is an author of more than 10 book chapters and more than 310 peer reviewed publications, including in the New England Journal of Medicine, Lancet Oncology, Blood, and the Journal of Clinical Oncology. Dr. Marks received his MBBS and PhD from the University of Melbourne.